IMA
Imagenebio Inc
NASDAQ · Pharmaceuticals
$6.91
-0.10 (-1.43%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 47.00M | 44.29M | 39.41M |
| Net Income | 6.79M | 4.55M | 5.11M |
| EPS | — | — | — |
| Profit Margin | 14.5% | 10.3% | 13.0% |
| Rev Growth | -8.8% | -0.9% | +2.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 20.07M | 19.74M | 17.02M |
| Total Equity | 40.17M | 39.52M | 44.51M |
| D/E Ratio | 0.50 | 0.50 | 0.38 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 10.10M | 9.89M | 9.22M |
| Free Cash Flow | 2.61M | 3.33M | 3.29M |